Document is current
Any future updates will be listed below
-
Authors
Goubet, Anne-Gaëlle
Rouanne, Mathieu
Derosa, Lisa
Kroemer, Guido https://orcid.org/0000-0002-9334-4405
Zitvogel, Laurence https://orcid.org/0000-0003-1596-0998
- License Information
-
More Information
Article History
Accepted: 18 May 2023
First Online: 11 July 2023
Competing interests
: L.Z. and A.-G.G. hold a patent entitled “A biomarker and compositions to increase the therapeutic index of neoadjuvant immunotherapy in muscle-invasive urothelial carcinoma” (No. PCT/EP2023/053977). L.Z. has held research contracts with 9 Meters Biopharma, Daiichi Sankyo and Pilege, and was on the Board of Directors of Transgene. L.Z. is a cofounder of everImmune, and its SAB President and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. Among these, patents were licensed to everImmune (US20210346438A1, US20200360449A1) and Transgene (US20200376052A1). L.D. is a consultant for everImmune, and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. L.D. is a member of everImmune SAB. G.K. has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Tollys and Vascage. G.K. has been consulting for Reithera. G.K. is on the Board of Directors of the Bristol Myers Squibb Foundation France. G.K. is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. G.K. is the inventor of patents covering therapeutic targeting of ageing, cancer, cystic fibrosis and metabolic disorders. Among these, patents were licensed to Bayer (WO2014020041-A1, WO2014020043-A1), Bristol Myers Squibb (WO2008057863-A1), Osasuna Therapeutics (WO2019057742A1), PharmaMar (WO2022049270A1 and WO2022048775-A1), Raptor Pharmaceuticals (EP2664326-A1), Samsara Therapeutics (GB202017553D0) and Therafast Bio (EP3684471A1). G.K.’s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. M.R. declares no competing interests.
